A patient who had therapeutic phlebotomy three weeks ago with serum iron of 30 µmol/L, transferrin saturation of 77 %, total iron‑binding capacity of 39 µmol/L, and ferritin of 579 µg/L—does he need another phlebotomy?

Yes, this patient needs another phlebotomy now.

With a ferritin of 579 µg/L and transferrin saturation of 77%, this patient remains significantly iron overloaded and requires continued therapeutic phlebotomy to reach target levels. The three-week interval since the last phlebotomy is appropriate timing for the induction phase of treatment 1.

Current Iron Status Analysis

Your patient's iron parameters indicate substantial ongoing iron overload:

• Ferritin 579 µg/L: This is far above all recommended targets. The 2022 EASL guidelines specify a target ferritin of 50 µg/L for the induction phase, with maintenance targets of 50-100 µg/L 1. Even the most relaxed expert opinions suggest ferritin <200 µg/L for women and <300 µg/L for men during maintenance only—not induction 1.

• Transferrin saturation 77%: This markedly elevated saturation (>50%) indicates active iron overload and supports the need for continued aggressive phlebotomy. While transferrin saturation may remain elevated even when ferritin normalizes in hemochromatosis, at this ferritin level it clearly reflects ongoing iron burden 1.

Treatment Phase and Frequency

This patient is clearly still in the induction phase of therapy, not maintenance. During induction:

• Phlebotomies should occur weekly or every 2 weeks (400-500 mL per session) depending on body weight and tolerance 1
• The three-week interval since last phlebotomy is reasonable and within guideline recommendations
• Continue this frequency until ferritin drops below 200 µg/L, then monitor more closely (every 1-2 sessions) as you approach the 50 µg/L target 1

Monitoring Requirements Before Next Phlebotomy

Check hemoglobin immediately before proceeding:

• If hemoglobin <12 g/dL: decrease phlebotomy frequency or reduce volume
• If hemoglobin <11 g/dL: discontinue phlebotomy and reassess clinically 1
• This is critical to avoid iatrogenic iron deficiency, which can develop even in hemochromatosis patients and causes symptomatic complications 2

Ongoing Management Algorithm

1. Continue weekly to biweekly phlebotomies until ferritin <200 µg/L
2. Measure ferritin monthly (or after every 4th phlebotomy) during this phase 1
3. Check hemoglobin at each phlebotomy session before proceeding 1
4. Once ferritin drops below 200 µg/L, increase monitoring to every 1-2 sessions to avoid overshooting the 50 µg/L target
5. Transition to maintenance phase (phlebotomy every 1-4 months) only after achieving target ferritin of 50-100 µg/L 1

Critical Pitfalls to Avoid

Do not stop phlebotomy prematurely. The elevated transferrin saturation combined with ferritin >500 µg/L indicates substantial residual iron burden that requires removal to prevent organ damage, including hepatic fibrosis, cirrhosis, and hepatocellular carcinoma risk 1.

Do not over-treat. Monitor hemoglobin closely—symptomatic iron deficiency can develop in hemochromatosis patients despite the underlying disorder, causing unnecessary morbidity 2. Ferritin levels <20 µg/L significantly increase iron absorption and indicate overtreatment 1.

Consider checking folate and cobalamin levels periodically in patients requiring numerous phlebotomies, supplementing if deficient 1.